{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:44Z","timestamp":1792431704082,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.dadr.2023.100133","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T13:47:15Z","timestamp":1673358435000},"page":"100133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-003X","authenticated-orcid":false,"given":"Christian","family":"Heidbreder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Fudala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dadr.2023.100133_bib0001","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.dadr.2023.100133_bib0002","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"2","key":"10.1016\/j.dadr.2023.100133_bib0003","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0004","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","article-title":"Addressing racial and ethnic disparities in the use of medications for opioid use disorder","volume":"40","author":"Andraka-Christou","year":"2021","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.dadr.2023.100133_bib0006","doi-asserted-by":"crossref","unstructured":"ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update, 2020. https:\/\/www.asam.org\/Quality-Science\/quality\/2020-national-practice-guideline. doi:10.1097\/ADM.0000000000000633.","DOI":"10.1097\/ADM.0000000000000633"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1988.13","article-title":"A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts","volume":"43","author":"Bickel","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3565(25)20047-7","article-title":"Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans","volume":"247","author":"Bickel","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.dadr.2023.100133_bib0009","article-title":"Continued posttrial benefits of buprenorphine extended release: RECOVER study findings","author":"Boyett","year":"2022","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.dadr.2023.100133_bib0010","unstructured":"Braeburn Inc., 2022. FDA Accepts Braeburn's New Drug Application Resubmission For BRIXADI\u2122 (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder. Cision PR Newswire, Chicago. https:\/\/www.prnewswire.com\/news-releases\/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301698779.html (Accessed December 14, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0011","unstructured":"Braeburn Pharmaceuticals, Inc., 2018. Braeburn announces FDA advisory committee recommends approval of CAM2038 buprenorphine depot for the treatment of opioid use disorder. https:\/\/braeburnrx.com\/braeburn-announces-fda-advisory-committee-recommends-approval-of-cam2038-buprenorphine-depot-for-the-treatment-of-opioid-use-disorder\/ (Accessed December 14, 2022)."},{"issue":"7","key":"10.1016\/j.dadr.2023.100133_bib0012","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/aje\/kwu190","article-title":"Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis","volume":"180","author":"Brogly","year":"2014","journal-title":"Am. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.15288\/jsad.2019.80.393","article-title":"Medications for maintenance treatment of opioid use disorder in adolescents: a narrative review and assessment of clinical benefits and potential risks","volume":"80","author":"Camenga","year":"2019","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.dadr.2023.100133_bib0014","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1749-6632.2011.06352.x","article-title":"The history of the development of buprenorphine as an addiction therapeutic","volume":"1248","author":"Campbell","year":"2012","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.dadr.2023.100133_bib0015","unstructured":"Casetext, 2015. Psychopharmacologic Drugs Advisory Committee; Notice of Meeting. https:\/\/casetext.com\/federal-register\/psychopharmacologic-drugs-advisory-committee-notice-of-meeting-16 (Accessed December 14, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0016","unstructured":"Centers for Disease Control and Prevention (CDC), 2022. Vital Statistics Rapid Release: Provisional Drug Overdose Data. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm (Accessed December 14, 2022)."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13722-022-00288-4","article-title":"Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study","volume":"17","author":"Cheng","year":"2022","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.dadr.2023.100133_bib0018","unstructured":"Comprehensive Addiction and Recovery Act (CARA), Pub. L. No 114\u2013198, 2016, July 22."},{"issue":"9","key":"10.1016\/j.dadr.2023.100133_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol. Assess."},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/00952990.2021.1992773","article-title":"Extended-release buprenorphine outcomes among treatment resistant veterans","volume":"48","author":"Cotton","year":"2022","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.dadr.2023.100133_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109389","article-title":"Recovery from opioid use disorder: a 4-year post-clinical trial outcomes study","volume":"234","author":"Craft","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"193","key":"10.1016\/j.dadr.2023.100133_bib0022","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride","volume":"23","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2023.100133_bib0023","unstructured":"Drug Addiction Treatment Act of 2000 (DATA 2000), 2000, October 17. Pub. L. No. 106\u2013310."},{"issue":"2","key":"10.1016\/j.dadr.2023.100133_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J. Addict. Med."},{"issue":"8","key":"10.1016\/j.dadr.2023.100133_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14045","article-title":"Monthly patient volumes of buprenorphine-waivered clinicians in the US","volume":"3","author":"Duncan","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.dadr.2023.100133_bib0026","first-page":"1","article-title":"Envisioning minimally disruptive opioid use disorder care","author":"Englander","year":"2022","journal-title":"J. Gen. Intern. Med."},{"issue":"8","key":"10.1016\/j.dadr.2023.100133_bib0027","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14620","article-title":"Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder","volume":"114","author":"Evans","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2023.100133_bib0028","unstructured":"emc, 2020, November 24. Temgesic Injection 1\u00a0ml, Summary of Product Characteristics. Indivior UK Limited, Slough, UK. https:\/\/www.medicines.org.uk\/emc\/product\/1141\/smpc#gref (Accessed December 14, 2022)."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-019-00436-7","article-title":"Medications for treatment of opioid use disorder among persons living with HIV","volume":"16","author":"Fanucchi","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.dadr.2023.100133_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103492","article-title":"Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence","volume":"100","author":"Farrell","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2023.100133_bib0031","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3917\/rfas.073.0153","article-title":"Public regulation measures for a sensitive drug: the case of Subutex\u00ae, opiate replacement therapy","volume":"3\u20134","author":"Feroni","year":"2007","journal-title":"French J. Social Affairs (Revue fran\u00e7aise des affaires sociales)"},{"issue":"8","key":"10.1016\/j.dadr.2023.100133_bib0032","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction"},{"issue":"10","key":"10.1016\/j.dadr.2023.100133_bib0033","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(98)00008-8","article-title":"Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts","volume":"50","author":"Fudala","year":"1998","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.dadr.2023.100133_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/15504263.2020.1726549","article-title":"Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: a literature review","volume":"16","author":"Ghabrash","year":"2020","journal-title":"J. Dual Diagn."},{"issue":"12","key":"10.1016\/j.dadr.2023.100133_bib0036","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/add.13073","article-title":"A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence","volume":"110","author":"Gisev","year":"2015","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.dadr.2023.100133_bib0037","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S2468-2667(19)30060-X","article-title":"The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study","volume":"4","author":"Gisev","year":"2019","journal-title":"Lancet Public Health"},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0038","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0376-8716(00)00109-5","article-title":"Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study","volume":"60","author":"Gossop","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2023.100133_bib0039","series-title":"Trends in Substance Abuse Research","first-page":"1","article-title":"Human experimental therapeutic models in opioid dependence: translational research advances and implications","author":"Greenwald","year":"2006"},{"key":"10.1016\/j.dadr.2023.100133_bib0040","series-title":"The Routledge Handbook of Philosophy and Science of Addiction","first-page":"478","article-title":"Opioid substitution treatment and harm minimization approaches","author":"Greenwald","year":"2018"},{"issue":"11","key":"10.1016\/j.dadr.2023.100133_bib0041","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0042","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","article-title":"Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices","volume":"61","author":"Greenwald","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0043","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A neuropharmacological model to explain buprenorphine induction challenges","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann. Emerg. Med."},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0044","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jsat.2011.06.005","article-title":"Patterns in admission delays to outpatient methadone treatment in the United States","volume":"41","author":"Gryczynski","year":"2011","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0045","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1080\/08897077.2022.2060423","article-title":"Opioid harm reduction: a scoping review of physician and system-level gaps in knowledge, education, and practice","volume":"43","author":"Gugala","year":"2022","journal-title":"Subst. Abus."},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0046","first-page":"761","article-title":"Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review","volume":"28","author":"Guillen","year":"2022","journal-title":"Telemed. J. E Health"},{"key":"10.1016\/j.dadr.2023.100133_bib0047","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","article-title":"Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder","volume":"78","author":"Haasen","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"issue":"8","key":"10.1016\/j.dadr.2023.100133_bib0048","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr."},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.dadr.2023.100133_bib0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"10173","key":"10.1016\/j.dadr.2023.100133_bib0051","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0052","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamapsychiatry.2020.4402","article-title":"Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 Pandemic","volume":"78","author":"Holland","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2023.100133_bib0053","unstructured":"Indivior Inc., 2022, June. SUBLOCADE\u2122 Full Prescribing Information. North Chesterfield, VA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209819s010lbl.pdf"},{"key":"10.1016\/j.dadr.2023.100133_bib0054","series-title":"Federal Regulation of Methadone Treatment","first-page":"96","article-title":"Committee on federal regulations of methadone treatment, division of biobehavioral sciences and mental disorders in rettig","year":"1995"},{"issue":"2 Suppl","key":"10.1016\/j.dadr.2023.100133_bib0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0056","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch. Gen. Psychiatry"},{"issue":"20","key":"10.1016\/j.dadr.2023.100133_bib0057","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0058","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/epirev\/mxaa011","article-title":"The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms","volume":"42","author":"Jones","year":"2020","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.dadr.2023.100133_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108783","article-title":"Characteristics and correlates of US clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic","volume":"225","author":"Jones","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.dadr.2023.100133_bib0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11606-020-06448-z","article-title":"Factors associated with long-term retention in buprenorphine-based addiction treatment programs: a systematic review","volume":"37","author":"Kennedy","year":"2022","journal-title":"J. Gen. Intern. Med."},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0061","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance","volume":"11","author":"Klaman","year":"2017","journal-title":"J Addict Med"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0062","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.dadr.2023.100133_bib0064","unstructured":"Kolberg R., 1995. Bridges to Baltimore: NIDA's Addiction Research Center. https:\/\/nihsearch.cit.nih.gov\/catalyst\/back\/95.05\/a.nida.html. (Accessed December 14, 2022)."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/ADM.0000000000000820","article-title":"Utilization of medications for opioid use disorder across US states: relationship to treatment availability and overdose mortality","volume":"16","author":"Krawczyk","year":"2021","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.dadr.2023.100133_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the US?: a yearly assessment from 2010 to 2019","author":"Krawczyk","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"7","key":"10.1016\/j.dadr.2023.100133_bib0067","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jcph.665","article-title":"Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder","volume":"56","author":"Laffont","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.dadr.2023.100133_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1052113","article-title":"Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder","volume":"13","author":"Laffont","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0069","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/ADM.0000000000000523","article-title":"Disparities between US opioid overdose deaths and treatment capacity: a geospatial and descriptive analysis","volume":"13","author":"Langabeer","year":"2019","journal-title":"J. Addict. Med."},{"issue":"5","key":"10.1016\/j.dadr.2023.100133_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ajad.12925","article-title":"Brief report: low-barrier buprenorphine initiation predicts treatment retention among Latinx and non-Latinx primary care patients","volume":"28","author":"Lee","year":"2019","journal-title":"Am. J. Addict."},{"issue":"9","key":"10.1016\/j.dadr.2023.100133_bib0071","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23032","article-title":"Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"3\u20134","key":"10.1016\/j.dadr.2023.100133_bib0072","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"Lewis","year":"1985","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2023.100133_bib0073","first-page":"7","article-title":"In pursuit of the Holy Grail. Nathan B Eddy Award Address","volume":"179","author":"Lewis","year":"1999","journal-title":"NIDA Res. Monogr."},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266142","article-title":"Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials","volume":"17","author":"Lim","year":"2022","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1016\/j.dadr.2023.100133_bib0075","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0076","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0077","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study","volume":"13","author":"Ling","year":"2019","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.dadr.2023.100133_bib0078","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/SAR.S198361","article-title":"Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the treatment effectiveness assessment","volume":"10","author":"Ling","year":"2019","journal-title":"Subst. Abuse Rehabil."},{"key":"10.1016\/j.dadr.2023.100133_bib0079","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cct.2018.11.015","article-title":"Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): study design and participant characteristics","volume":"76","author":"Ling","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.dadr.2023.100133_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"J. Subst. Abuse Treat."},{"issue":"5","key":"10.1016\/j.dadr.2023.100133_bib0081","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study","volume":"14","author":"Ling","year":"2020","journal-title":"J. Addict. Med."},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2020.100179","article-title":"Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis","volume":"2","author":"Link","year":"2020","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0083","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0084","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","article-title":"The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis","volume":"93","author":"Marsch","year":"1998","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","article-title":"Bioavailability of sublingual buprenorphine","volume":"37","author":"Mendelson","year":"1997","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.dadr.2023.100133_bib0086","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0006-3223(96)00266-1","article-title":"Buprenorphine and naloxone interactions in methadone maintenance patients","volume":"41","author":"Mendelson","year":"1997","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0087","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050804","article-title":"Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256752","article-title":"Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients","volume":"17","author":"Moss","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.dadr.2023.100133_bib0089","unstructured":"Narcotic Addict Treatment Act of 1974 (NATA), Pub. L. No. 93-281, p. 29, 1974, May 14. https:\/\/www.congress.gov\/bill\/93rd-congress\/senate-bill\/1115\/text (Accessed December 14, 2022)."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","article-title":"Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder","volume":"36","author":"Nasser","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0092","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/00912709922008236","article-title":"Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations","volume":"39","author":"Nath","year":"1999","journal-title":"J. Clin. Pharmacol."},{"issue":"S1","key":"10.1016\/j.dadr.2023.100133_bib0093","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: drug testing in 2020","volume":"24","author":"Niles","year":"2021","journal-title":"Popul. Health Manage."},{"key":"10.1016\/j.dadr.2023.100133_bib0094","unstructured":"Office of National Drug Control Policy (ONDCP) Reauthorization Act of 2006, Pub. L. No. 109-469, 2006. https:\/\/www.congress.gov\/109\/plaws\/publ469\/PLAW-109publ469.pdf (Accessed December 14, 2022)"},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1360-0443.2009.02856.x","article-title":"The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service","volume":"105","author":"Oliver","year":"2010","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.dadr.2023.100133_bib0096","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156973","article-title":"Modeling buprenorphine reduction of fentanyl-induced respiratory depression","volume":"7","author":"Olofsen","year":"2022","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.dadr.2023.100133_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228755","article-title":"Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in US healthcare settings","volume":"15","author":"Pro","year":"2020","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.dadr.2023.100133_bib0098","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s11524-020-00486-y","article-title":"Opioid overdose-related emergency department visits and accidental deaths during the COVID-19 pandemic","volume":"97","author":"Rodda","year":"2020","journal-title":"J. Urban Health"},{"key":"10.1016\/j.dadr.2023.100133_bib0099","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2288-14-68","article-title":"Accounting for individual differences and timing of events: estimating the effect of treatment on criminal convictions in heroin users","volume":"14","author":"R\u00f8islien","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.dadr.2023.100133_bib0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst. Abuse Rehabil."},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0101","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12954-022-00592-x","article-title":"Interim opioid agonist treatment for opioid addiction: a systematic review","volume":"19","author":"Sams\u00f3 Jofra","year":"2022","journal-title":"Harm Reduct. J."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0103","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0376-8716(99)00012-5","article-title":"Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet","volume":"56","author":"Schuh","year":"1999","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0104","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-021-00223-z","article-title":"Prior national drug abuse treatment clinical trials network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 \"optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)\"","volume":"16","author":"Shulman","year":"2021","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.dadr.2023.100133_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108176","article-title":"Signal of increased opioid overdose during COVID-19 from emergency medical services data","volume":"214","author":"Slavova","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2023.100133_bib0106","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.dadr.2023.100133_bib0107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.31887\/DCNS.2017.19.3\/msoyka","article-title":"Treatment of opioid dependence with buprenorphine: current update","volume":"19","author":"Soyka","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.dadr.2023.100133_bib0108","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/phar.2676","article-title":"Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review","volume":"42","author":"Spreen","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.dadr.2023.100133_bib0109","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees","volume":"39","author":"Stein","year":"2018","journal-title":"Subst. Abus."},{"key":"10.1016\/j.dadr.2023.100133_bib0110","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), 2021a. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey On Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, Maryland. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35325\/NSDUHFFRPDFWHTMLFiles2020\/2020NSDUHFFR1PDFW102121.pdf (Accessed December 14, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0111","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), 2021b. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020, Data on Substance Abuse Treatment Facilities. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, Maryland. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35313\/2020_NSSATS_FINAL.pdf (Accessed December 14, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0112","unstructured":"Substance Use-disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, Pub. L. No 115-271, 2018. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-115publ271\/html\/PLAW-115publ271.htm (Accessed December 14, 2022)"},{"issue":"12","key":"10.1016\/j.dadr.2023.100133_bib0113","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1007\/s11606-021-06904-4","article-title":"Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment","volume":"36","author":"Taylor","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.dadr.2023.100133_bib0114","unstructured":"Titan Pharmaceuticals, Inc., 2022, June. PROBUPHINE\u00ae Full Prescribing Information. San Francisco, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204442s012lbl.pdf (Accessed December 15, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0115","unstructured":"US Department of Health and Human Services (HHS), Office of the Surgeon General, 2018. Facing Addiction in America: The Surgeon General's Spotlight On Opioids. HHS, Washington, D.C. https:\/\/addiction.surgeongeneral.gov\/sites\/default\/files\/Spotlight-on-Opioids_09192018.pdf (Accessed December 14, 2022)"},{"key":"10.1016\/j.dadr.2023.100133_bib0116","unstructured":"US Food and Drug Administration (FDA), n.d.a. DRUGS@FDA: fDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=204242 (Accessed October 7, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0117","unstructured":"US FDA,\u00a0 n.d.b. DRUGS@FDA: fDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=205637 (Accessed October 7, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0118","unstructured":"US FDA,\u00a0 n.d.c. DRUGS@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=208042 (Accessed October 7, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0119","unstructured":"US FDA, 1972. Methadone Listing as New Drug With Special Requirements and Opportunity for Hearing in: Federal Register Volume 37, Issue 242 (December 15, 1972). Office of the Federal Register, National Archives and Records Administration, Washington, D. C., pp. 26790\u201326807. https:\/\/www.govinfo.gov\/content\/pkg\/FR-1972-12-15\/pdf\/FR-1972-12-15.pdf (Accessed December 14, 2022)"},{"key":"10.1016\/j.dadr.2023.100133_bib0120","unstructured":"US FDA, 2009, December. Guidance for Industry Patient-Reported Outcome Measures: use in Medical Product Development to Support Labeling Claims. https:\/\/www.fda.gov\/media\/77832\/download (Accessed October 7, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0121","unstructured":"US FDA, 2020, October. Opioid Use Disorder: endpoints for Demonstrating Effectiveness of Drugs Guidance for Industry, https:\/\/www.fda.gov\/media\/114948\/download (Accessed October 7, 2022)."},{"key":"10.1016\/j.dadr.2023.100133_bib0122","unstructured":"US FDA, 2022. Orange Book: approved Drug Products with Therapeutic Equivalence Evaluations. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm. (Accessed December 14, 2022)."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0123","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2005.06.010","article-title":"Medications development: successes and challenges","volume":"108","author":"Vocci","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.dadr.2023.100133_bib0124","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.dadr.2023.100133_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0126","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","article-title":"COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States","volume":"26","author":"Wang","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.dadr.2023.100133_bib0127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2009.03.008","article-title":"Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence","volume":"103","author":"White","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2023.100133_bib0128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-021-00220-2","article-title":"Comparing rapid micro-induction and standard induction of buprenorphine\/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial","volume":"16","author":"Wong","year":"2021","journal-title":"Addict. Sci. Clin. Pract."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:32:09Z","timestamp":1757421129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724623000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":126,"alternative-id":["S2772724623000033"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100133","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100133"}}